Nanobiotix S.A. (NANO.PA)
Nanobiotix S.A.
60 rue de Wattignies
Paris 75012
France
33 1 40 26 04 70
https://www.nanobiotix.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 110
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Laurent Levy Ph.D. | Co-Founder, President of the Executive Board & CEO | 713.87k | N/A | 1973 |
| Mr. Bart Van Rhijn | Chief Financial & Business Officer and Member of Executive Board | 628.49k | N/A | 1973 |
| Ms. Anne-Juliette Hermant M.A. | Chief People Officer & Member of Executive Board | 354.9k | N/A | 1974 |
| Dr. Louis Kayitalire M.D. | Chief Medical Officer | 500.8k | N/A | 1958 |
| Mr. Earl J. Bergey Ph.d. | Co-Founder | N/A | N/A | 1955 |
| Mr. Craig West CFA | Senior Vice President of Investor Relations | N/A | N/A | N/A |
| Mr. Brandon Owens | VP of Strategic Marketing & Corporate Communication | N/A | N/A | N/A |
| Ms. Margaret Galluzzi | VP & Global Head of Clinical Operations | N/A | N/A | N/A |
| Dr. Leonard A. Farber M.D. | Chief Clinical and Medical Affairs Officer & Chairman of the Scientific Advisory Board | N/A | N/A | N/A |
Description
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
Corporate Governance
Nanobiotix S.A.’s ISS Governance QualityScore as of November 1, 2024 is 8. The pillar scores are Audit: 9; Board: 7; Shareholder Rights: 7; Compensation: 10.
